DEBBANE RAYMOND
SEC CIK 1053890 · EDGAR
BoughtSold
Most active insiders at LXRX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Artal Group S.A. | Dir, 10% | $2.00M | — |
| 2 | DEBBANE RAYMOND | Dir | $723.0K | — |
| 3 | Martens Rachel Yap | SVP, Partnerships, Corp Strat | — | — |
| 4 | Gopinathan Suma | SVP, Discovery | — | — |
| 5 | Artal Participations S.a r.l. | Dir, 10% | — | — |
| 6 | Cheung Ivan | Dir | — | — |
| 7 | Exton Michael | CEO, Dir | — | — |
| 8 | Sullivan Diane E. | Dir | — | — |
| 9 | McDermott Wendy | SVP, Human Resources | — | — |
| 10 | Granowitz Craig B | SVP, Chief Medical Off | — | — |
Transactions 23
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-04 16:09 | 2026-06-03 | LXRX | LEXICON PHARMACEUTICALS, INC. | DEBBANE RAYMOND | Dir | M - OptEx | $0.00 | +89.3K | 2.00M | +5% | $0 |
| 2026-02-27 | 2026-02-25 | LXRX | LEXICON PHARMACEUTICALS, INC. | DEBBANE RAYMOND | Dir | P - Purchase | $1.49 | +2,000 | 1.91M | +0.1% | +$2,980 | |
| 2026-02-25 | 2026-02-23 | LXRX | LEXICON PHARMACEUTICALS, INC. | DEBBANE RAYMOND | Dir | P - Purchase | $1.47 | +100.0K | 1.90M | +6% | +$147.0K | |
| M | 2026-02-23 | 2026-02-19+ | LXRX | LEXICON PHARMACEUTICALS, INC. | DEBBANE RAYMOND | Dir | P - Purchase | $1.47 | +150.0K | 1.70M | +10% | +$220.0K |
| M | 2026-02-18 | 2026-02-13+ | LXRX | LEXICON PHARMACEUTICALS, INC. | DEBBANE RAYMOND | Dir | P - Purchase | $1.31 | +268.5K | 1.65M | +19% | +$353.1K |
| D | 2025-05-13 | 2025-05-13 | LXRX | LEXICON PHARMACEUTICALS, INC. | DEBBANE RAYMOND | Dir | M - OptEx | $0.00 | +36.8K | 1.39M | +3% | $0 |
| D | 2024-04-29 | 2024-04-28 | LXRX | LEXICON PHARMACEUTICALS, INC. | DEBBANE RAYMOND | Dir | M - OptEx | $0.00 | +8,032 | 1.35M | +0.6% | $0 |
| M | 2023-10-12 | 2023-10-10+ | LXRX | LEXICON PHARMACEUTICALS, INC. | DEBBANE RAYMOND | Dir | P - Purchase | $1.10 | +1.00M | 1.19M | +521% | +$1.10M |
| D | 2023-05-22 | 2023-05-21 | LXRX | LEXICON PHARMACEUTICALS, INC. | DEBBANE RAYMOND | Dir | M - OptEx | $0.00 | +9,302 | 340.8K | +3% | $0 |
| 2023-05-11 | 2023-05-09 | WW | WW INTERNATIONAL, INC. | DEBBANE RAYMOND | Former Dir | A - Grant | $0.00 | +835 | 134.4K | +0.6% | $0 | |
| 2023-04-05 | 2023-04-03 | WW | WW INTERNATIONAL, INC. | DEBBANE RAYMOND | Dir | A - Grant | $0.00 | +2,053 | 133.6K | +2% | $0 | |
| 2023-01-04 | 2023-01-02 | WW | WW INTERNATIONAL, INC. | DEBBANE RAYMOND | Dir | A - Grant | $0.00 | +5,067 | 131.5K | +4% | $0 | |
| 2022-11-15 | 2022-11-10 | WW | WW INTERNATIONAL, INC. | DEBBANE RAYMOND | Dir | P - Purchase | $4.27 | +75.0K | 126.4K | +146% | +$320.2K | |
| 2022-10-05 | 2022-10-03 | WW | WW INTERNATIONAL, INC. | DEBBANE RAYMOND | Dir | A - Grant | $0.00 | +4,595 | 51.4K | +10% | $0 | |
| I | 2022-08-09 | 2022-08-05 | LXRX | LEXICON PHARMACEUTICALS, INC. | DEBBANE RAYMOND | Dir, 10% | P - Purchase | $2.50 | +147.4K | 5.45M | +3% | +$368.5K |
| I | 2022-08-01 | 2022-08-01 | LXRX | LEXICON PHARMACEUTICALS, INC. | DEBBANE RAYMOND | Dir, 10% | P - Purchase | $2.50 | +982.6K | 5.30M | +23% | +$2.46M |
| I | 2022-08-01 | 2022-08-01 | LXRX | LEXICON PHARMACEUTICALS, INC. | DEBBANE RAYMOND | Dir | P - Purchase | $2.50 | +982.6K | 5.30M | +23% | +$2.46M |
| 2022-07-06 | 2022-07-04 | WW | WW INTERNATIONAL, INC. | DEBBANE RAYMOND | Dir | A - Grant | $0.00 | +2,745 | 46.8K | +6% | $0 | |
| D | 2022-05-02 | 2022-04-30 | LXRX | LEXICON PHARMACEUTICALS, INC. | DEBBANE RAYMOND | Dir | M - OptEx | $0.00 | +4,024 | 331.5K | +1% | $0 |
| 2022-04-06 | 2022-04-04 | WW | WW INTERNATIONAL, INC. | DEBBANE RAYMOND | Dir | A - Grant | $0.00 | +1,797 | 44.1K | +4% | $0 | |
| 2022-01-05 | 2022-01-03 | WW | WW INTERNATIONAL, INC. | DEBBANE RAYMOND | Dir | A - Grant | $15.90 | +1,179 | 42.3K | +3% | +$18.7K | |
| 2021-10-06 | 2021-10-04 | WW | WW INTERNATIONAL, INC. | DEBBANE RAYMOND | Dir | A - Grant | $18.78 | +998 | 41.1K | +2% | +$18.7K | |
| 2021-07-07 | 2021-07-05 | WW | WW INTERNATIONAL, INC. | DEBBANE RAYMOND | Dir | A - Grant | $35.84 | +523 | 40.1K | +1% | +$18.7K |
Purchase Sale Sale after option exercise All abbreviations